|Mr. Darrin R. Uecker||Pres, CEO & Director||393.62k||N/A||1966|
|Mr. Brian B. Dow||CFO, Sr. VP of Fin. & Admin., Treasurer and Sec.||285.75k||N/A||1969|
|Dr. Richard Nuccitelli Ph.D.||Chief Science Officer||N/A||N/A||N/A|
|Dr. Holly Hartman Ph.D., J.D.||VP of Bus. Devel. & Corp. Strategy||N/A||N/A||N/A|
|Mr. David Danitz||VP of Engineering||N/A||N/A||N/A|
Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.
Pulse Biosciences, Inc.’s ISS Governance QualityScore as of July 1, 2018 is 9. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 5; Compensation: 10.